JP2014111603A5 - - Google Patents

Download PDF

Info

Publication number
JP2014111603A5
JP2014111603A5 JP2013265373A JP2013265373A JP2014111603A5 JP 2014111603 A5 JP2014111603 A5 JP 2014111603A5 JP 2013265373 A JP2013265373 A JP 2013265373A JP 2013265373 A JP2013265373 A JP 2013265373A JP 2014111603 A5 JP2014111603 A5 JP 2014111603A5
Authority
JP
Japan
Prior art keywords
dose
administered
antibody
medicament according
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013265373A
Other languages
English (en)
Japanese (ja)
Other versions
JP6143664B2 (ja
JP2014111603A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014111603A publication Critical patent/JP2014111603A/ja
Publication of JP2014111603A5 publication Critical patent/JP2014111603A5/ja
Application granted granted Critical
Publication of JP6143664B2 publication Critical patent/JP6143664B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2013265373A 1999-05-07 2013-12-24 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 Expired - Lifetime JP6143664B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13301899P 1999-05-07 1999-05-07
US60/133,018 1999-05-07
US13962199P 1999-06-17 1999-06-17
US60/139,621 1999-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010002582A Division JP2010159255A (ja) 1999-05-07 2010-01-08 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017055885A Division JP2017149726A (ja) 1999-05-07 2017-03-22 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療

Publications (3)

Publication Number Publication Date
JP2014111603A JP2014111603A (ja) 2014-06-19
JP2014111603A5 true JP2014111603A5 (enExample) 2014-10-02
JP6143664B2 JP6143664B2 (ja) 2017-06-07

Family

ID=26830960

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000616821A Withdrawn JP2002544174A (ja) 1999-05-07 2000-05-04 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
JP2010002582A Withdrawn JP2010159255A (ja) 1999-05-07 2010-01-08 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
JP2013265373A Expired - Lifetime JP6143664B2 (ja) 1999-05-07 2013-12-24 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
JP2017055885A Pending JP2017149726A (ja) 1999-05-07 2017-03-22 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
JP2018005367A Withdrawn JP2018058906A (ja) 1999-05-07 2018-01-17 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000616821A Withdrawn JP2002544174A (ja) 1999-05-07 2000-05-04 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
JP2010002582A Withdrawn JP2010159255A (ja) 1999-05-07 2010-01-08 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017055885A Pending JP2017149726A (ja) 1999-05-07 2017-03-22 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
JP2018005367A Withdrawn JP2018058906A (ja) 1999-05-07 2018-01-17 Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療

Country Status (21)

Country Link
US (12) US7820161B1 (enExample)
EP (3) EP1637160A3 (enExample)
JP (5) JP2002544174A (enExample)
KR (2) KR20020027311A (enExample)
CN (1) CN100358577C (enExample)
AT (1) ATE311199T1 (enExample)
AU (2) AU777970C (enExample)
BR (1) BR0011197A (enExample)
CA (3) CA2944644C (enExample)
CY (1) CY1105295T1 (enExample)
DE (1) DE60024436T2 (enExample)
DK (1) DK1176981T3 (enExample)
ES (1) ES2254174T3 (enExample)
HK (1) HK1043312B (enExample)
HU (1) HUP0201009A2 (enExample)
IL (1) IL146005A0 (enExample)
MX (1) MXPA01011279A (enExample)
NO (1) NO20015417L (enExample)
NZ (1) NZ514914A (enExample)
PL (1) PL200134B1 (enExample)
WO (1) WO2000067796A1 (enExample)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0011197A (pt) * 1999-05-07 2002-02-19 Genentech Inc Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura
EP1645291A1 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
HK1046635B (en) * 1999-06-09 2009-10-09 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
JP2004512262A (ja) * 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
DK2283861T3 (en) * 2000-11-20 2016-02-15 Canadian Blood Services METHOD OF TREATING TROMBOCYTOPENIA WITH MONOCLONAL IVIG
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
ES2388170T3 (es) 2001-08-24 2012-10-09 Uvic Industry Partnerships Inc. Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
AU2003215365A1 (en) 2002-02-21 2003-09-09 Duke University Treatment methods using anti-cd22 antibodies
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
AU2003215732B2 (en) * 2002-03-01 2009-12-17 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
NZ535297A (en) 2002-04-23 2008-05-30 Cargill Inc A method of producing monatin by converting tyrptophan or indole-3-lactic acid to monatin
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
WO2004032867A2 (en) * 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2003209753A1 (en) * 2003-01-27 2004-08-23 Crucell Holland B.V. Internalising human binding molecules against cd72
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US9416187B2 (en) 2003-05-09 2016-08-16 Duke University CD-20 specific antibodies and methods of employing same
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005005462A2 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
US20060275289A1 (en) * 2003-08-28 2006-12-07 Takamasa Watanabe Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient
EP2302067B1 (en) 2003-10-21 2014-03-05 Cargill, Incorporated Production of monatin and monatin precursors
HRP20100303T1 (hr) * 2003-11-05 2010-07-31 Roche Glycart Ag Cd20 antitijela s povećanim afinitetom vezivanja fc receptora i efektorskim djelovanjem
RU2006126078A (ru) * 2003-12-19 2008-01-27 Дженентек, Инк. (Us) Детектирование cd20 в терапии аутоиммунных заболеваний
EP1570857A1 (en) * 2004-02-27 2005-09-07 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for inhibiting the transendothelal migration of cells such as leukocytes or tumor cells by a CD81 binding agent and uses thereof
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2564529A1 (en) * 2004-05-05 2005-12-15 Genentech, Inc. Preventing autoimmune disease
KR20070029733A (ko) * 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
BRPI0510885A (pt) * 2004-06-04 2007-12-26 Genentech Inc método de tratamento de lúpus e artigo industrializado
EP2292749A3 (en) 2004-07-30 2011-12-21 Novozymes A/S Alanine 2, 3 aminomutases
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
AU2005294666A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
ES2481641T3 (es) * 2004-10-21 2014-07-31 Ono Pharmaceutical Co., Ltd. Uso de receptor inmunosupresor
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
AU2006341528A1 (en) 2005-04-26 2007-12-06 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
AU2006244445B2 (en) * 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
CN101223448B (zh) 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
WO2007053184A2 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
JP2009502936A (ja) 2005-07-25 2009-01-29 トルビオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２０特異的結合分子の単一投与量
EP1924286A4 (en) * 2005-08-12 2010-01-13 Garvan Inst Med Res PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP2386639A3 (en) 2005-11-21 2012-05-30 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EA019971B1 (ru) 2006-03-07 2014-07-30 Верениум Корпорейшн Альдолазы, кодирующие их нуклеиновые кислоты и способы их получения и применения
JP5441417B2 (ja) 2006-03-07 2014-03-12 カーギル・インコーポレイテッド アルドース、それをコードする核酸、ならびにそれを生成および使用する方法
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MY165625A (en) * 2006-12-26 2018-04-18 Ct Inmunologia Molecular Pharmaceutical composition comprising an anti- cd6 monoclonal antibody useful for the diagnosis and treatment of rheumatoid arthritis
MX2009010620A (es) * 2007-04-02 2009-11-25 Genentech Inc Marcadores biologicos predictivos de respuesta de artritis reumatoide a antagonistas de celula-b.
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
NZ583019A (en) 2007-07-31 2011-05-27 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CN101970493A (zh) 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
ATE513856T1 (de) 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
RU2390334C1 (ru) * 2008-12-17 2010-05-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ лечения рассеянного склероза
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
AU2011252864B2 (en) 2010-05-14 2015-11-05 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (CR2) targeting groups
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3590949T1 (sl) 2010-10-01 2022-09-30 Modernatx, Inc. Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
WO2013024097A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
MX354988B (es) 2011-10-25 2018-03-28 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2847220A1 (en) * 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
SI2895507T1 (sl) 2012-09-11 2019-03-29 Institucio Catalana De Recerca I Estudis Avancats Diagnostični postopek za detektiranje avtoimunske bolezni in povezane zadeve
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
JP6366111B2 (ja) 2012-12-13 2018-08-01 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 有効性の改善および毒性の減少のための、抗体およびｓｎ−３８からなるイムノコンジュゲートの投薬
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
GB201302597D0 (en) 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015001352A1 (en) 2013-07-03 2015-01-08 The University Court Of The University Of Edinburgh Novel regenerative therapy
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
GB201313235D0 (en) 2013-07-24 2013-09-04 Univ Edinburgh Antiviral Compositions Methods and Animals
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
GB201318170D0 (en) 2013-10-14 2013-11-27 Univ Edinburgh Proteins with Diagnostic and Therapeutic Uses
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EA037561B1 (ru) 2014-06-23 2021-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
US20170226209A1 (en) * 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
PT3699198T (pt) 2014-11-17 2025-04-29 Regeneron Pharma Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
US20180200335A1 (en) * 2014-11-28 2018-07-19 The University Of Tokyo B Cell Activation Inhibitor, and Therapeutic Agent For Autoimmune Diseases
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
UA127809C2 (uk) 2015-06-24 2024-01-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
KR20250052494A (ko) 2015-10-02 2025-04-18 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
CA3016917A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
WO2025052171A1 (en) 2016-07-07 2025-03-13 The University Court Of The University Of Edinburgh Alpha-synuclein detection assay
CN115028728A (zh) 2016-09-27 2022-09-09 高地和群岛大学 抗原生物标志物
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
ES2908662T3 (es) * 2017-01-24 2022-05-03 I Mab Biopharma Us Ltd Anticuerpos anti-CD73 y usos de los mismos
JP2020512314A (ja) 2017-03-27 2020-04-23 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． サシツズマブゴビテカンとＲＡＤ５１阻害剤を用いたＴｒｏｐ−２発現トリプルネガティブ乳癌の治療
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
GB201712952D0 (en) 2017-08-11 2017-09-27 Univ Edinburgh Immunomodulatory agent
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US11692042B2 (en) 2018-03-09 2023-07-04 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
JOP20200342A1 (ar) 2018-07-05 2020-12-30 Incyte Corp مشتقات بيرازين مدمجة كمثبطات a2a/a2b
CN112041348B (zh) 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
FI3844189T3 (fi) 2018-08-31 2025-03-05 Regeneron Pharma Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12022550509A1 (en) 2019-09-06 2023-03-20 Servier Lab Anti-cd73 antibodies
AU2020419293A1 (en) 2020-01-03 2022-07-28 Incyte Corporation CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
MX2022007575A (es) 2020-01-03 2022-09-23 Incyte Corp Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
AU2021411952A1 (en) 2020-12-29 2023-08-10 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
GB202102931D0 (en) 2021-03-02 2021-04-14 Invizius Ltd Peritoneal fluid composition
GB202202728D0 (en) 2022-02-28 2022-04-13 Invizius Ltd Peritoneal fluid composition

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4724213A (en) 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
NZ225599A (en) 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
CA1340565C (en) 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
WO1991001133A1 (en) 1989-07-19 1991-02-07 Arthur Allen Vandenbark T cell receptor peptides as therapeutics for autoimmune and malignant disease
AU7566991A (en) 1990-03-14 1991-10-10 Biomembrane Institute, The Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
SK285960B6 (sk) 1991-07-25 2007-12-06 Biogen Idec Inc. Rekombinantné protilátky na liečenie ľudí
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1995009652A1 (en) * 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
EP0663836B1 (en) 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
DE69332859T2 (de) 1992-11-13 2003-12-18 Idec Pharmaceuticals Corp., San Diego Konsensus-kozak-sequenzen zur säugetier-exprimierung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
GB9323542D0 (en) 1993-11-15 1994-01-05 Univ Alberta Lymphocyte marker specific for corhn's disease
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
WO1995034320A2 (en) 1994-06-07 1995-12-21 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
WO1996031229A1 (en) 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US20030180290A1 (en) 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US5877299A (en) 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
JPH11513669A (ja) 1995-10-13 1999-11-24 アメリカ合衆国 ジスルフィド安定化抗体フラグメントを含む免疫毒素
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
JP4751493B2 (ja) 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
CA2255941A1 (en) 1996-05-31 1997-12-04 David L. Ennist Prevention of graft-versus-host disease with t-cells including polynucleotides encoding negative selective markers
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
JP2000516594A (ja) * 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
ATE233573T1 (de) 1996-10-17 2003-03-15 Immunomedics Inc Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
GB9705744D0 (en) 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1215497B1 (en) 1997-12-16 2009-01-07 University Of Zurich Diagnostics for transmissible spongiform encephalopathy
US6280957B1 (en) 1998-02-04 2001-08-28 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allo-transplantation
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1071752B1 (en) 1998-04-21 2003-07-09 Micromet AG CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
MY136203A (en) 1998-08-11 2008-08-29 Idec Pharma Corp Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6555320B1 (en) * 1998-09-01 2003-04-29 Mayo Foundation For Medical Education And Research Methods and materials for evaluating rheumatoid arthritis
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US6410319B1 (en) * 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2000027428A1 (en) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
MY155913A (en) 1998-11-09 2015-12-15 Biogen Inc Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
ATE432083T1 (de) * 1999-02-25 2009-06-15 Nat Jewish Ct For Immunology A Produkt und methode zur behandlung von konditionen assoziiert mit rezeptor- desensibilisierung
EP1035172A3 (en) 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
BR0011197A (pt) 1999-05-07 2002-02-19 Genentech Inc Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6404323B1 (en) 1999-05-25 2002-06-11 Varatouch Technology Incorporated Variable resistance devices and methods
HK1046635B (en) 1999-06-09 2009-10-09 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
HK1047702A1 (zh) 1999-07-12 2003-03-07 Genentech Inc. 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答
JP2003513012A (ja) 1999-08-11 2003-04-08 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
AU1072701A (en) 1999-10-04 2001-05-10 Chiron Corporation Cd40 antagonist for treating psoriasis
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2390412A1 (en) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
IL151906A0 (en) 2000-03-24 2003-04-10 Chiron Corp Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
AU8729101A (en) 2000-03-31 2001-10-15 Idec Pharma Corp Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
US20020004587A1 (en) 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001080884A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
EP1305045A1 (en) 2000-07-12 2003-05-02 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
AU2002213357A1 (en) 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
EP1373321A2 (en) 2001-01-29 2004-01-02 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
JP4679035B2 (ja) 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
EP1404366A4 (en) 2001-06-14 2006-06-07 Intermune Inc COMBINED THERAPY USING INTERFERON GAMMA AND SPECIFIC B-CELL ANTIBODIES
FR2827636B1 (fr) 2001-07-19 2003-11-28 Eurocopter France Systeme de regulation du regime d'un moteur d'un helicoptere
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
DE60322426D1 (enExample) 2002-12-16 2008-09-04 Genentech Inc
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
WO2005005462A2 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
RU2370775C2 (ru) 2003-07-29 2009-10-20 Дженентек, Инк. Анализ нейтрализующих антител и его применение
MXPA06002134A (es) 2003-08-29 2006-05-31 Genentech Inc Terapia de trastornos oculares.
BRPI0416243A (pt) 2003-11-05 2007-01-09 Palingen Inc método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
RU2006126078A (ru) 2003-12-19 2008-01-27 Дженентек, Инк. (Us) Детектирование cd20 в терапии аутоиммунных заболеваний
RU2006126099A (ru) 2003-12-19 2008-01-27 Дженентек, Инк. (Us) Детектирование cd20 при отторжении трансплантата
WO2005115453A2 (en) 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
MXPA06011824A (es) 2004-04-16 2006-12-15 Genentech Inc Ensayo para anticuerpos.
WO2005113003A2 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
CA2564529A1 (en) 2004-05-05 2005-12-15 Genentech, Inc. Preventing autoimmune disease
WO2005114218A2 (en) 2004-05-15 2005-12-01 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
BRPI0510885A (pt) 2004-06-04 2007-12-26 Genentech Inc método de tratamento de lúpus e artigo industrializado
US20060062787A1 (en) 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
AU2005294666A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
AR052056A1 (es) 2004-12-17 2007-02-28 Genentech Inc Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo
CN101128586A (zh) 2004-12-22 2008-02-20 健泰科生物技术公司 制备可溶性多跨膜蛋白的方法
ZA200705459B (en) 2005-01-13 2008-09-25 Genentech Inc Treatment method
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
JP2008538767A (ja) 2005-04-22 2008-11-06 ジェネンテック・インコーポレーテッド Ｃｄ２０抗体による認知症又はアルツハイマー病の治療方法
CN101223448B (zh) 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage

Similar Documents

Publication Publication Date Title
JP2014111603A5 (enExample)
JP2017149726A5 (enExample)
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
JP2012193216A5 (enExample)
MX384376B (es) Formas de dosificación de liberación inmediata disuasivas del abuso, en forma de partículas recubiertas con capas múltiples que comprenden un analgésico narcótico susceptible de abuso o sobredosis.
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
JP2014141525A5 (enExample)
EP4512394A3 (en) Dosage forms and use thereof
CL2014002324A1 (es) Metodo para lentificar el avance, demorar o tratar la prediabetes en un paciente con sobrepeso u obeso que comprende la administracion de empagliflozina y uno o varios fármacos antiobesidad y composición farmacéutica que comprende a dichos farmacos.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
RU2015134422A (ru) Применение левоцитиризина и монтелукаста при лечении васкулита
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol
MX348595B (es) Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
ECSP17008187A (es) Formas de dosificación farmacéutica
AR109019A1 (es) Formas de dosis orales en bajas dosis para el tratamiento de enfermedades